Related references
Note: Only part of the references are listed.Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Hiroji Iwata et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer
David L. Rimm et al.
MODERN PATHOLOGY (2019)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone
Aurelie Bellanger et al.
JOURNAL OF PATHOLOGY (2017)
Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers
Takayuki Iwamoto et al.
ONCOTARGET (2017)
Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer
Consuelo Morigi
ECANCERMEDICALSCIENCE (2017)
Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours
Cornelia M. Focke et al.
HISTOPATHOLOGY (2016)
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature
M. Marous et al.
ANNALS OF ONCOLOGY (2015)
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer
Arran K. Turnbull et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
An international study to increase concordance in Ki67 scoring
Mei-Yin C. Polley et al.
MODERN PATHOLOGY (2015)
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review
A. Charehbili et al.
CANCER TREATMENT REVIEWS (2014)
A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers
Nhan T. Nguyen et al.
MOLECULAR ONCOLOGY (2014)
ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial-Mesenchymal Transition and Invasion
Julie A. Vendrell et al.
CANCER RESEARCH (2012)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
Y. H. Chia et al.
BRITISH JOURNAL OF CANCER (2010)
Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients
Balazs Gyoerffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Share Paper
